Slide 1: Corporate Presentation
1 Corporate Presentation Exhibit 99.1
Slide 2: Disclaimer and Other Information
2 Disclaimer and Other Information Forward-looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expect
Slide 3: Quantum-Si Highlights
3 Quantum-Si Highlights Experienced team + board from leading life sciences companies Large and growing proteomics market opportunity valued at $75B+ Differentiated core technology, patent- protected, extensible to wide range of proteomics applications Partnerships in place spanning commercializatio
Slide 4: Proteins Are the Core of Biological Discoveries Across Many End Markets
4 Proteins Are the Core of Biological Discoveries Across Many End Markets Academic Research Pharma + Biotech Industrial Defense Clinical Diagnostics Translational Research Agriculture
Slide 5: Proteome Complexity
5 Proteome Complexity GENOME TRANSCRIPTOME Alternative Promoters Alternative splicing mRNA editing Post-translational Modifications ~20–25,000 GENES ~100,000 TRANSCRIPTS PROTEOME >1,000,000 PROTEOFORMS
Slide 6: PTMs and Proteoforms are the Next Frontier in Human Health
6 Su P G Me Methylation (Lys/Arg) Phosphorylation (Ser/Thr/Tyr) Palmitoylation (Cys) Sumoylation (Lys) Ubiquitination (Lys) Citrullination (Arg) AC Pal Ub Glycosylation (Ser/Thr/Asn) Acetylation (Lys) Translation Cit A post-translational modification (PTM) is a chemical change to an amino acid made
Slide 7: The Study of Proteoforms Extends to Many Disease Areas and Thousands of Unique Proteins
7 The Study of Proteoforms Extends to Many Disease Areas and Thousands of Unique Proteins Human Proteoform Project: https://www.science.org/doi/10.1126/sciadv.abk0734 Complete coverage of the proteome would require tens of thousands or more unique, site-specific affinity reagents Only single-molecul
Slide 8: Proteomics is a Large and Growing Market Poised for Significant Growth
8 Proteomics is a Large and Growing Market Poised for Significant Growth Research $20B+ Emerging Clinical $55B+ Deep proteoform-level analysis will be needed to fully define and characterize the biomarkers with highest medical value Large-scale screening studies designed to identify clinically relev
Slide 9: Specialized Platforms With High Capital Costs Limit Adoption Outside of Core Labs in Proteomics
9 Specialized Platforms With High Capital Costs Limit Adoption Outside of Core Labs in Proteomics Many specialized platforms needed to fully interrogate the proteome Technical tradeoffs when selecting between the breadth of protein coverage and depth of insights High capital costs with the top-end i
Slide 10: The Customer Data is Clear
10 The Customer Data is Clear Researchers need a breadth of capabilities to answer their biological questions Number of Unique Applications One Two Three or more Number of PTMs Required One Two Three or more More than 50 detailed study proposals submitted by prospective customers >50% require three
Slide 11: Moving Beyond the Core Lab: Proteus Will Enable Deep Protein Analysis
11 Moving Beyond the Core Lab: Proteus Will Enable Deep Protein Analysis and Accelerate the Field of Proteomics Automation simplifies laboratory workflow, increases throughput, and minimizes the need for specialized staff Affordable, allowing any lab — anywhere — to be a proteomics core lab Single-m
Slide 12: Current Platform: Platinum Pro
12 Current Platform: Platinum® Pro Platinum Pro sequences individual peptides by capturing the fluorescent signal from each amino acid Sequence Analyze Our analysis software automates the work and provides amino acid-level insights; offline option available for users who can’t access the cloud Libra
Slide 13: Leveraging Platinum Pro for Market Development and Commercial Infrastructure Build for Proteus Launch
13 Leveraging Platinum Pro for Market Development and Commercial Infrastructure Build for Proteus Launch Global distribution network in place, covering all major markets Expanding user base across many market segments including academic, biopharma, defense, and agriculture Focusing on independent da
Slide 14: Publication Pipeline is Growing
14 Publication Pipeline is Growing All publications Proteoforms relevant to biological interactions Peptide barcoding Single-molecule binding kinetics Single-amino acid variants associated with disease
Slide 15: Proteus On Track to Far Exceed Platinum Pro at Launch
15 Proteus On Track to Far Exceed Platinum Pro at Launch * Proteus is in development. Estimated launch specifications. Switch from semiconductor to optical architecture with patterned nanowell array Liquid handling automation dramatically simplifies workflow 40× more sequencing throughput per consum
Slide 16: Proteus Next-generation Architecture
16 Proteus Next-generation Architecture Platinum® Pro + 2M Chip • Integrated semiconductor consumable with 2 million wells • Benchtop instrument with manual workflow Proteus + KinetIQ Array • Simple, passive consumable with estimated 80 million wells at launch • Benchtop instrument with imaging syst
Slide 17: Increased Sequencing Output and Lower Costs of the Nanowell Array
17 The Increased Sequencing Output and Lower Costs of the Nanowell Array is Broadly Enabling More samples per run with 40× the output per consumable compared to Platinum Pro Deep analysis of a single sample to address complex mixtures or rare events like variants or PTMs Multiplexing samples to achi
Slide 18: Accelerating the Core Sequencing Technology and Analytics to Unlock the Highest-value Applications
18 Accelerating the Core Sequencing Technology and Analytics to Unlock the Highest-value Applications Robust PTM detection and multi-PTM profiling Single-amino acid variant detection Sequencing of variable regions of antibodies Biothreat detection and surveillance
Slide 19: Proteus Automation Greatly Simplifies the Sequencing Workflow
19 Proteus Automation Greatly Simplifies the Sequencing Workflow and Makes New Lab Startup Even Easier A single reagent module per run — simply unbox and load Pipette your sample(s) into the cartridge and hit Run Over 30 individual reagent tubes to handle to process four samples Over 100 pipetting s
Slide 20: Milestones on the Path to Proteus Launch in 2026
20 Milestones on the Path to Proteus Launch in 2026 External customer collaborations initiated (summer 2026) End-to-end sequencing on fully integrated systems (Q2) Platinum upgrade program released (Q3) Instrument list price released (Q2) Internal V&V (Q4) Sequencing on Proteus prototype Fully integ
Slide 21: Proteus Architecture Supports Our Long-term Platform Roadmap
21 Proteus Architecture Supports Our Long-term Platform Roadmap Requirements Proteus 2.0 (up to 10B) Proteus (80M+) Proteus Plus (up to 320M) Consumable architecture scales to billions of wells 10× sequencing output from assay improvements alone Future instruments capable of up to 10B reads Instrume
Slide 22: QSI is Well-positioned to Build Upon Our First-to-market Advantage
22 QSI is Well-positioned to Build Upon Our First-to-market Advantage and Extend Our Leadership Into the Future Extend our technology lead through best-in- class R&D innovation and execution Execute on development roadmap to deliver a compelling Proteus launch Build a partner ecosystem to accelerate
Slide 23: Quantum-Si Q&A
QUANTUM SI Q&A